While preclinical studies in SOD1 mutant mice demonstrate that memantine treatment delays disease progression and improves motor neuron survival, likely through inhibition of spinal cord NMDA receptors (Wang and Zhang, 2005; Joo et al., 2007), these findings have not translated to clinical benefit in ALS patients. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.